Home LiteratureArticle Details
PMID: 24027197 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

A hormone-DNA repair circuit governs the response to genotoxic insult.

Cancer discovery ·Vol. 3 ·No. 11 ·2013-11-00 ·Pages 1254-71

Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, Ma T, Den RB, Dicker AP, Feng FY, Knudsen KE

Abstract

Alterations in DNA repair promote tumor development, but the impact on tumor progression is poorly understood. Here, discovery of a biochemical circuit linking hormone signaling to DNA repair and therapeutic resistance is reported. Findings show that androgen receptor (AR) activity is induced by DNA damage and promotes expression and activation of a gene expression program governing DNA repair. Subsequent investigation revealed that activated AR promotes resolution of double-strand breaks and resistance to DNA damage both in vitro and in vivo. Mechanistically, DNA-dependent protein kinase catalytic subunit (DNAPKcs) was identified as a key target of AR after damage, controlling AR-mediated DNA repair and cell survival after genotoxic insult. Finally, DNAPKcs was shown to potentiate AR function, consistent with a dual role in both DNA repair and transcriptional regulation. Combined, these studies identify the AR-DNAPKcs circuit as a major effector of DNA repair and therapeutic resistance and establish a new node for therapeutic intervention in advanced disease. The present study identifies for the fi rst time a positive feedback circuit linking hormone action to the DNA damage response and shows the significant impact of this process on tumor progression and therapeutic response. These provocative findings provide the foundation for development of novel nodes of therapeutic intervention for advanced disease.

MeSH Terms
Androgen Antagonists/pharmacology Animals Antineoplastic Agents, Hormonal/pharmacology Cell Line, Tumor Cell Survival/genetics DNA Damage/genetics,radiation effects DNA Repair/drug effects DNA-Activated Protein Kinase/genetics,metabolism DNA-Binding Proteins/genetics,metabolism Drug Resistance, Neoplasm/genetics Feedback, Physiological Gene Expression Regulation, Neoplastic Humans Male Mice Mice, Nude Nuclear Proteins/genetics,metabolism Prostatic Neoplasms/genetics,pathology,therapy Receptors, Androgen/genetics,metabolism Signal Transduction/genetics Xenograft Model Antitumor Assays
Chemicals
Androgen Antagonists Antineoplastic Agents, Hormonal DNA-Binding Proteins Nuclear Proteins Receptors, Androgen DNA-Activated Protein Kinase PRKDC protein, human Prkdc protein, mouse
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Goodwin Jonathan F
Departments of 1Cancer Biology, 2Urology, and 3Radiation Oncology, and 4Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania; 5Michigan Center for Translational Pathology, 6Department of Radiation Oncology, and 7Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan.
Schiewer Matthew J
Dean Jeffry L
Schrecengost Randy S
de Leeuw Renée
Han Sumin
Ma Teng
Den Robert B
Dicker Adam P
Feng Felix Y
Knudsen Karen E
References (71)
71 references, click to expand
  1. Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage.
    Cancer Res. 2012 Jan 1;72(1):13-7 PMID: 22180494
  2. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.
    Cell. 2009 Jul 23;138(2):245-56 PMID: 19632176
  3. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer.
    Clin Cancer Res. 2009 Aug 1;15(15):4792-8 PMID: 19638458
  4. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression.
    J Clin Invest. 2010 Dec;120(12):4478-92 PMID: 21099110
  5. Overexpression of DNA repair genes is associated with metastasis: a new hypothesis.
    Mutat Res. 2008 Jul-Aug;659(1-2):49-55 PMID: 18308619
  6. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes.
    Oncogene. 2010 Nov 18;29(46):6085-98 PMID: 20818418
  7. The DNA-damage response in human biology and disease.
    Nature. 2009 Oct 22;461(7267):1071-8 PMID: 19847258
  8. E2F1 and p53 transcription factors as accessory factors for nucleotide excision repair.
    Int J Mol Sci. 2012 Oct 19;13(10):13554-68 PMID: 23202967
  9. ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation.
    Cancer Res. 2004 Apr 1;64(7):2390-6 PMID: 15059890
  10. Punctuated evolution of prostate cancer genomes.
    Cell. 2013 Apr 25;153(3):666-77 PMID: 23622249
  11. Transcriptional activation of DNA-dependent protein kinase catalytic subunit gene expression by oestrogen receptor-alpha.
    EMBO Rep. 2010 Mar;11(3):208-13 PMID: 20111054
  12. Castration therapy results in decreased Ku70 levels in prostate cancer.
    Clin Cancer Res. 2013 Mar 15;19(6):1547-56 PMID: 23349316
  13. Modification of the DNA damage response by therapeutic CDK4/6 inhibition.
    J Biol Chem. 2012 Aug 17;287(34):29075-87 PMID: 22733811
  14. Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?
    Urol Oncol. 2009 Jan-Feb;27(1):67-71 PMID: 19111801
  15. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway.
    Annu Rev Biochem. 2010;79:181-211 PMID: 20192759
  16. Regulation of DNA double-strand break repair pathway choice.
    Cell Res. 2008 Jan;18(1):134-47 PMID: 18157161
  17. P53 and the proteasome regulate androgen receptor activity.
    Cancer Biol Ther. 2012 May;13(7):553-8 PMID: 22407029
  18. Deficiency in the catalytic subunit of DNA-dependent protein kinase causes down-regulation of ATM.
    Cancer Res. 2005 Mar 1;65(5):1670-7 PMID: 15753361
  19. ARN-509: a novel antiandrogen for prostate cancer treatment.
    Cancer Res. 2012 Mar 15;72(6):1494-503 PMID: 22266222
  20. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation.
    Biochem Pharmacol. 2008 Oct 15;76(8):947-57 PMID: 18657518
  21. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining.
    Biochem J. 2009 Feb 1;417(3):639-50 PMID: 19133841
  22. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
    J Clin Oncol. 2012 Apr 20;30(12):1268-73 PMID: 22393101
  23. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking.
    Mol Cell. 2005 Sep 2;19(5):631-42 PMID: 16137620
  24. CBP and p300 histone acetyltransferases contribute to homologous recombination by transcriptionally activating the BRCA1 and RAD51 genes.
    PLoS One. 2012;7(12):e52810 PMID: 23285190
  25. DNA-PKcs expression predicts response to radiotherapy in prostate cancer.
    Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1179-85 PMID: 22494583
  26. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
    Lancet. 2011 Dec 17;378(9809):2104-11 PMID: 22056152
  27. Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers.
    Cancer Res. 2006 Aug 15;66(16):8219-26 PMID: 16912201
  28. Genomic instability--an evolving hallmark of cancer.
    Nat Rev Mol Cell Biol. 2010 Mar;11(3):220-8 PMID: 20177397
  29. Emerging roles of DNA-PK besides DNA repair.
    Cell Signal. 2011 Aug;23(8):1273-80 PMID: 21514376
  30. FEN1 functions in long patch base excision repair under conditions of oxidative stress in vertebrate cells.
    Mol Cancer Res. 2010 Feb;8(2):204-15 PMID: 20145043
  31. Targeting the DNA damage response in oncology: past, present and future perspectives.
    Curr Opin Oncol. 2012 May;24(3):316-24 PMID: 22476188
  32. The RAD51 gene family, genetic instability and cancer.
    Cancer Lett. 2005 Mar 10;219(2):125-35 PMID: 15723711
  33. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
    Cancer Res. 2008 Jun 1;68(11):4447-54 PMID: 18519708
  34. Abiraterone in prostate cancer: a new angle to an old problem.
    Clin Cancer Res. 2012 Apr 1;18(7):1848-54 PMID: 22451619
  35. Playing the end game: DNA double-strand break repair pathway choice.
    Mol Cell. 2012 Aug 24;47(4):497-510 PMID: 22920291
  36. Interaction of the double-strand break repair kinase DNA-PK and estrogen receptor-alpha.
    Mol Biol Cell. 2010 May 1;21(9):1620-8 PMID: 20219974
  37. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.
    Nature. 2005 Apr 14;434(7035):864-70 PMID: 15829956
  38. Genomic instability and cancer: an introduction.
    J Mol Cell Biol. 2011 Feb;3(1):1-3 PMID: 21278445
  39. Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.
    Oncogene. 2012 Apr 26;31(17):2153-63 PMID: 21909140
  40. Targeted therapies for breast cancer.
    J Clin Invest. 2011 Oct;121(10):3797-803 PMID: 21965336
  41. Targeting androgen receptor in estrogen receptor-negative breast cancer.
    Cancer Cell. 2011 Jul 12;20(1):119-31 PMID: 21741601
  42. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441.
    Cancer Res. 2006 May 15;66(10):5354-62 PMID: 16707462
  43. Use of γH2AX and other biomarkers of double-strand breaks during radiotherapy.
    Semin Radiat Oncol. 2010 Oct;20(4):223-31 PMID: 20832014
  44. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma.
    World J Gastroenterol. 2008 Oct 21;14(39):5945-61 PMID: 18932272
  45. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
    Lancet. 2009 Jan 24;373(9660):301-8 PMID: 19091394
  46. Radiation-induced genomic instability and its implications for radiation carcinogenesis.
    Oncogene. 2003 Sep 1;22(37):5848-54 PMID: 12947391
  47. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling.
    Nucl Recept Signal. 2008 Jun 27;6:e008 PMID: 18612376
  48. Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.
    Cancer Res. 2007 Jul 1;67(13):6192-203 PMID: 17616676
  49. Lack of prostate cancer radiosensitization by androgen deprivation.
    Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1002-7 PMID: 11704324
  50. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.
    N Engl J Med. 1997 Jul 31;337(5):295-300 PMID: 9233866
  51. Chromatin modifications and the DNA damage response to ionizing radiation.
    Front Oncol. 2013 Jan 22;2:214 PMID: 23346550
  52. Chicken progesterone receptor is phosphorylated by a DNA-dependent protein kinase during in vitro transcription assays.
    Mol Endocrinol. 1992 Jan;6(1):8-14 PMID: 1738374
  53. The DNA damage response: making it safe to play with knives.
    Mol Cell. 2010 Oct 22;40(2):179-204 PMID: 20965415
  54. Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells.
    J Biol Chem. 1998 Aug 7;273(32):20213-22 PMID: 9685369
  55. Cell cycle dependence of DNA-dependent protein kinase phosphorylation in response to DNA double strand breaks.
    J Biol Chem. 2005 Apr 15;280(15):14709-15 PMID: 15677476
  56. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.
    Cancer Res. 2008 Jul 1;68(13):5469-77 PMID: 18593950
  57. Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?
    Mol Endocrinol. 2012 Aug;26(8):1252-67 PMID: 22745190
  58. Dual roles of PARP-1 promote cancer growth and progression.
    Cancer Discov. 2012 Dec;2(12):1134-49 PMID: 22993403
  59. Autophosphorylation of the DNA-dependent protein kinase catalytic subunit is required for rejoining of DNA double-strand breaks.
    Genes Dev. 2002 Sep 15;16(18):2333-8 PMID: 12231622
  60. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
    Cancer Cell. 2010 May 18;17(5):443-54 PMID: 20478527
  61. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription.
    Science. 2006 Jun 23;312(5781):1798-802 PMID: 16794079
  62. DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability.
    Prog Nucleic Acid Res Mol Biol. 1988;35:95-125 PMID: 3065826
  63. Formation of the androgen receptor transcription complex.
    Mol Cell. 2002 Mar;9(3):601-10 PMID: 11931767
  64. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86.
    Br J Cancer. 2009 Sep 1;101(5):816-21 PMID: 19672258
  65. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells.
    J Biol Chem. 2005 Mar 18;280(11):10827-33 PMID: 15640154
  66. Targeting the androgen receptor pathway in prostate cancer.
    Curr Opin Pharmacol. 2008 Aug;8(4):440-8 PMID: 18674639
  67. Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma.
    Radiat Res. 2010 Dec;174(6):703-11 PMID: 21128793
  68. The life and death of DNA-PK.
    Oncogene. 2005 Feb 3;24(6):949-61 PMID: 15592499
  69. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man.
    Cancer Cell. 2013 Jan 14;23(1):35-47 PMID: 23260764
  70. Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
    Science. 2009 May 8;324(5928):787-90 PMID: 19359544
  71. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.
    Nature. 2005 Apr 14;434(7035):907-13 PMID: 15829965
Article Info
Journal
Cancer discovery
Abbr.
Cancer Discov
ISSN
2159-8290
Published
2013-11-00
Epub
2013-00-11
Pages
1254-71
Language
English
Region
United States
NLM ID
101561693
PMCID
PMC3823813
Subset
IM
Grants
NCI NIH HHS · P30 CA056036 · United States
NCI NIH HHS · R01 CA099996 · United States
NCI NIH HHS · R01 CA159945 · United States
NCI NIH HHS · P30-CA-56036 · United States
Corrections
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com